Table 2 Background, characteristics and diagnosis methods for hepatocellular carcinoma
Protocol-A | Protocol-B | Protocol-C | Protocol-D | ||
|---|---|---|---|---|---|
Background* | |||||
Hepatitis B | 5 (3.5) | 8 (6.8) | 6 (6.9) | 6 (9.0) | |
Hepatitis C | 36 (25.0) | 35 (29.9) | 17 (19.5) | 19 (28.4) | |
LC | 104 (72.2) | 75 (64.1) | 65 (74.7) | 42 (62.7) | |
LC-B | 9 (6.3) | 8 (6.8) | 3 (3.4) | 2 (3.0) | |
LC-C | 75 (52.1) | 51 (43.6) | 45 (51.7) | 28 (41.8) | |
LC-Alcoholic | 13 (9.0) | 9 (7.7) | 11 (12.6) | 13 (19.4) | |
NASH | 5 (3.5) | 1 (0.9) | 0.(0.0) | 0 (0.0) | |
Others | 5 (3.5) | 9 (7.7) | 8 (9.2) | 2 (3.0) | |
Fatty liver | 1 (0.7) | 0 (0.0) | 3 (3.4) | 2 (3.0) | |
Others | 2 (1.4) | 2 (1.7) | 0 (0.0) | 0 (0.0) | |
Characteristics | |||||
Size of tumor** (mm) | 17.08 ± 6.42 | 16.85 ± 5.88 | 16.70 ± 6.27 | 16.60 ± 6.29 | |
Range | 3.0-30.0 | 5.6-30.0 | 7.0-30.0 | 6.6 − 29.0 | |
<20 mm | 89 (61.8) | 73 (62.4) | 62 (71.3) | 45 (67.2) | |
>20 mm | 55 (38.2) | 44 (37.6) | 25 (28.7) | 22 (32.8) | |
Number of tumors | 1-3 | 109 (75.7) | 97 (82.9) | 65 (74.7) | 47 (70.1) |
4-6 | 14 (9.7) | 8 (6.8) | 7 (8.0) | 6 (9.0) | |
7-9 | 6 (4.2) | 3 (2.6) | 1 (1.1) | 4 (6.0) | |
>10 | 15 (10.4) | 9 (7.7) | 14 (16.1) | 10 (14.9) | |
Diagnosis methods* | |||||
Biopsy | 5 (3.5) | 1 (0.9) | 0 (0.0) | 0 (0.0) | |
CE-MRI | 33 (22.9) | 39 (33.3) | 31 (35.6) | 14 (20.9) | |
CTAP/CTHA | 10 (6.9) | 9 (7.7) | 10 (11.5) | 9 (13.4) | |
Angiography | 29 (20.1) | 43 (36.8) | 10 (11.5) | 26 (38.8) | |
Lipiodol CT | 12 (8.3) | 15 (12.8) | 4 (4.6) | 3 (4.5) | |
Sonography | 42 (29.1) | 56 (47.9) | 40 (46.0) | 28 (41.8) | |
Growth of tumor | 45 (31.3) | 27 (23.1) | 37 (42.5) | 11 (16.4) | |
Increased tumor markers | 78 (54.2) | 70 (59.8) | 45 (51.7) | 34 (50.7) | |